Accueil>>Signaling Pathways>> Microbiology & Virology>> HBV>>Isoscopoletin

Isoscopoletin (Synonyms: Esculetin 7-methyl ether, 7-methoxy-6-Hydroxycoumarin, 7-Methoxyesculetin)

Catalog No.GC36342

L'isoscopolétine (6-hydroxy-7-méthoxycoumarine) est un constituant actif des feuilles d'Artemisia argyi.

Products are for research use only. Not for human use. We do not sell to patients.

Isoscopoletin Chemical Structure

Cas No.: 776-86-3

Taille Prix Stock Qté
1mg Please Inquire Please Inquire
5mg
72,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Isoscopoletin (6-Hydroxy-7-methoxycoumarin) is an active constituent in Artemisia argyi leaves. Isoscopoletin shows substantial inhibition against cell proliferation, with IC50s of 4.0 μM and 1.6 μM for human CCRF-CEM leukaemia cells and multidrug resistant subline CEM/ADR5000, respectively[1]. Isoscopoletin (6-Hydroxy-7-methoxycoumarin) possesses inhibitory activity against HBV replication[2].

[1]. Adams M, et al. Activity-guided isolation of scopoletin and isoscopoletin, the inhibitory active principles towards CCRF-CEM leukaemia cells and multi-drug resistant CEM/ADR5000 cells, from Artemisia argyi. Planta Med. 2006 Jul;72(9):862-4. [2]. Li H, et al. Evaluation of antiviral activity of compounds isolated from Ranunculus sieboldii and Ranunculus sceleratus. Planta Med. 2005 Dec;71(12):1128-33.

Avis

Review for Isoscopoletin

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Isoscopoletin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.